Senior Management Team

• John M. Krayacich. - President & Chief Executive Officer
• Stephen Bloch, M.D. - Chairman
• Kenneth R. Shaw, Ph.D. - Vice President, Research & Development
• Vincent Pieribone, Ph.D. - Founding Discovery Officer
• Julia Tsai, Ph.D. - Director, Drug Development

John M. Krayacich

President & Chief Executive Officer

John Krayacich joined Marinus Pharmaceuticals in 2008 as President, Chief Executive Officer and director after serving as the global head of neuroscience project management at Novartis Pharmaceuticals Corporation. As part of his role at Novartis, Mr. Krayacich acted as vice president and global program head of agomelatine, the first melatonergic antidepressant, and led the neuroscience drug development teams in the areas of major depressive disorder, general anxiety disorders, Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, spinal cord injury and bipolar disorder.

Prior to joining Novartis in 2003, Mr. Krayacich was Vice President of worldwide marketing (neurology) at Pfizer Pharmaceuticals, where he was responsible for a global marketing strategy and new product development.

Mr. Krayacich has more than 20 years of experience in the pharmaceutical industry with an emphasis on neurology product development and marketing. He started his career with Parke-Davis/Warner-Lambert Canada and advanced through a series of assignments in sales, North American and worldwide marketing, business development and global drug development. His work has included the development and commercialization of Lipitor®, Neurontin®, Lyrica®, Accupril®, Exelon® Patch, Focalin XR® and several neuroscience NCEs currently in development.

Steven Bloch, M.D.

Chairman

Stephen Bloch, MD joined Canaan Partners in June, 2002, initially as a Ewing Marion Kauffman Fellow. His investment targets include biopharmaceuticals (therapeutics and diagnostics), medical devices and healthcare infrastructure. Steve currently serves on the Board of Directors for Advanced Biohealing, Amicus Therapeutics, Marinus Pharmaceuticals, OmniSonics Medical Technologies and Viacor.

Prior to joining Canaan, Steve was a medical entrepreneur and practicing physician. He founded and was CEO of Radiology Management Sciences (RMS), a risk manager of diagnostic imaging services for health plans and provider networks. As medical director, he helped start Omnisonics Medical Technologies which is developing breakthrough products using acoustic energy for the treatment of vascular occlusive diseases. Additionally, he co-founded TeleRad, a teleradiology services company, and was an initial investor in OpenAir.com, an enterprise software company for professional services firms. Dr. Bloch started his business career as a strategic consultant with Arthur D. Little focused on pharmaceuticals and medical devices.

Dr. Bloch received his medical training as a radiologist at The Massachusetts General Hospital/Harvard Medical School and in internal medicine at The Lenox Hill Hospital/Cornell Medical School. He received his medical degree from the University of Rochester. He also received a MA in history of science and public policy from Harvard University and an AB degree in history from Dartmouth College.

Dr. Bloch became Chairman of the Marinus Pharmaceuticals Board in October 2007.

Kenneth R. Shaw, Ph.D.

Vice President, Research & Development

Dr. Shaw is a co-founder of Marinus and heads all non-clinical research and development operations at the Company. Dr. Shaw has over 20 years experience in the pharmaceutical industry. For the fifteen years prior to joining Marinus, Dr. Shaw was a primary force in growing Neurogen Corporation from 5 to over 200 employees. At Neurogen, he was Senior Vice President of Chemistry and Preclinical Development. This position involved managing all Rx activities involving Chemistry (Medicinal, Process and High Speed Synthesis), Drug Metabolism, Toxicology, Analytical Chemistry and Manufacturing. Dr. Shaw served as project leader on many of Neurogen’s collaborative programs. Through multiple collaborations, Dr. Shaw has been a member on internal Rx committees at Pfizer, Merck, Aventis and Schering-Plough.

Dr. Shaw began his career in 1983 at Ciba-Geigy after obtaining a Ph.D. in Organic Chemistry from Columbia University. At Ciba-Geigy, Dr. Shaw co-invented Selfotil® the first competitive NMDA antagonist which reached Phase III clinical trials and was a critical force in unifying Ciba-Geigy’s world-wide molecular modeling effort. He was also the youngest member appointed to the research and development oversight group for U.S. projects.

Vincent Pieribone, Ph.D.

Founding Discovery Officer

Dr. Pieribone is a co-founders of Marinus Pharmaceuticals, Inc. and has played an ongoing role in the Company's research. Dr. Pieribone is also an Associate Professor in Cellular and Molecular Physiology and Neurobiology at Yale University School of Medicine and heads the Laboratory of Cellular Neurophysiology. He received his B.S. and Ph.D. in Neurobiology from New York University.

Dr. Pieribone received postdoctoral training in the Nobel Institute of Neurophysiology at the Karolinska Institute in Stockholm Sweden, and in the Laboratory of Dr. Paul Greengard at The Rockefeller University. He has 15 years experience in in vivo neurophysiology, neuropharmacology and physiologic optical imaging.

Dr. Pieribone has co-authored over 60 scientific articles in scientific journals including Science, Nature, and the Proceedings of the National Academy of Science. He is currently a member of the NIH's Scientific Advisory Panel on Neuroscience SBIR grants and an ad hoc member of other governmental and non-governmental advisory panels.

Julia Tsai, Ph.D.

Director, Drug Development

Dr. Tsai joined Marinus Pharmaceuticals in September 2004 and is responsible for the daily drug development operations.

Prior to her doctoral training, Dr. Tsai conducted scientific research in Alzheimer’s Disease with Dr. Norman Relkin in the Department of Neurology at Weil School of Medicine of Cornell University, New York Presbyterian Hospital, and Dr. Paul Greengard at Rockefeller University. Dr. Tsai was also Clinical Study Coordinator for clinical drug trials in Alzheimer’s Disease in the Department of Neurology.

Dr. Tsai received her B.A. at Cornell University. Dr. Tsai received her Ph.D. in Neuroscience and Physiology at the Sackler Institute of Graduate Biomedical Sciences, New York University School of Medicine. She conducted her doctoral thesis on the synaptic pathogenesis associated with Alzheimer’s Disease and explored potential therapies. She has co-authored numerous scientific papers and abstracts and has presented her work at several scientific meetings.